Stay updated with breaking news from Markh Eckman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
As compared with low-molecular-weight heparin, direct oral anticoagulants (DOACs) were more clinically effective and more cost-effective for treating cancer-associated thrombosis.
Apixaban dominated enoxaparin and edoxaban; rivaroxaban was slightly more effective than apixaban.
Research conducted by UC Davis Comprehensive Cancer Center and the University of Cincinnati shows that direct oral anti-coagulant (DOAC) drugs are more effective and are more cost-effective than low molecular weight heparin (LMWH) for treating cancer-associated thrombosis (CAT).
Direct oral anti-coagulant (DOAC) drugs are more effective and are more cost-effective than low molecular weight heparin (LMWH) for treating cancer-associated thrombosis (CAT), shows research conducted by UC Davis Comprehensive Cancer Center and the University of Cincinnati.